PRNewsWire
15 Jun 2026, 12:47 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Elanco received USDA approval for TruCan Ultra Lyme-L4, the first and only 1/2 mL combination vaccine for canine Lyme disease and leptospirosis. — Product approval creates a new revenue stream and provides a unique competitive advantage through a first-to-market combination formulation.
+0.40TruCan Ultra Lyme-L4 is expected to begin shipping within the next 30 days. — Immediate commercial availability means the company can begin recognizing revenue from the new product in the very near term.
+0.20Leptospirosis vaccination is now recognized as a 'core vaccine' per AAHA guidelines, meaning all dogs should be vaccinated regardless of lifestyle. — Expanding the target addressable market from 'at-risk' dogs to all dogs increases the potential volume of sales for the vaccine.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company received USDA approval for a first-of-its-kind combination vaccine for dogs, expanding its product portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
9h ago
